Aerovate Therapeutics, Inc.
AVTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.54 | -7.53 | -39.61 | 4.60 |
| FCF Yield | -2.69% | -0.27% | -0.16% | -0.27% |
| EV / EBITDA | -35.22 | -256.20 | -471.60 | -435.48 |
| Quality | ||||
| ROIC | -97.05% | -73.93% | -41.64% | -13.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 0.75 | 0.76 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -25.08% | -44.77% | -42.56% | -250.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.28 | 0.40 | 2.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -354.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,109.79 | -13,821.69 | 0.00 |